Arthneeti
SM

Sahajanand Medical Technologies Ltd

Q2 FY27Healthcare Equipment & Supplies

Sahajanand Medical Technologies Q2 Results 2026 (FY27): Guides 10–20% Revenue Growth, Margins Up

Q2 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹373Cr
Net profit
₹26Cr
Margin
17.6%

What the Q2 FY27 call signalled

2 of 3 strong

RevenueModerate growth
MarginMargins slightly up
CapexCapex planned
Price₹493
Market cap₹5.0K Cr
P/E69.8

The short version

Revenue is expected to grow at mid to high teens in constant currency terms for current and next year. Revenue growth expected in mid to high teens in constant currency for FY 2027 and FY 2028.

From Sahajanand Medical Technologies Ltd's Q2 FY27 earnings-call transcript · updated 10 Nov 2026.

How did Sahajanand Medical Technologies' revenue grow in the September 2026 quarter?

Moderate growth
  • Revenue is expected to grow at mid to high teens in constant currency terms for current and next year.
  • Growth will come from both vascular intervention and structural heart segments, with structural heart expected to grow faster due to its larger, faster-growing market and smaller current base.
  • India business may see a tailwind from new regulations limiting reuse of medical devices, though this will only moderately boost growth.
  • International business opportunities exist in adding new product approvals in countries where the company already has presence, accelerating sales ramp-up.
  • New product launches such as the Hydra TAVI platform and next-generation valve expected to contribute to revenue growth.

2 more points from Sahajanand Medical Technologies Ltd's call on revenue

Create a free account to keep reading this call

What happened to Sahajanand Medical Technologies' margins in Q2 FY27?

See what Sahajanand Medical Technologies Ltd said on profitability & margins — free account, 30 seconds.

What capex is Sahajanand Medical Technologies planning?

Capex planned
  • Capex guidance for FY 2027 and FY 2028 is approximately INR 70 crores per year.
  • Around INR 44 crores have already been spent in H1 FY 2027.
  • Capex is focused on three main areas:
  • Vertical integration to bring outsourced processes in-house.
  • Automation improvements.
  • Maintenance capex for the legacy plant in Sachin.
  • A small part of the capex is allocated to capacity enhancement.
  • Current capacity is adequate for at least 1.5 years; future capacity additions will be incremental.

2 more points from Sahajanand Medical Technologies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

Guidance-ranked
1OSEL Devices
Rev 1Mar 3
2Avience Biomedicals
Rev 1Mar 3
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 3Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Sahajanand Medical Technologies raising money or cutting debt?

See what Sahajanand Medical Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Sahajanand Medical Technologies' order book?

Some related insights include: - The company is experiencing strong demand and growth, driven by new product launches and favorable reimbursement policies, especially in the IVUS business. - Trading business as a percentage of revenue has been picking up, with partnerships fueling faster-than-anticipated growth. - There is ongoing progress in product pipeline development, including TAVI 2.0, AVDC platform, PTCA catheters, and others scheduled for launch within the next 1-3 years.

2 more points from Sahajanand Medical Technologies Ltd's call on order book

Create a free account to keep reading this call

Sahajanand Medical Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2025Q2 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Sahajanand Medical Technologies Ltd Q2 FY27 results — key figures

Sahajanand Medical Technologies Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue373
Operating profit (EBITDA)66
Operating margin17.6%
Profit before tax40
Net profit (PAT)26
EPS (₹)2.63

Source: Sahajanand Medical Technologies Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹373 Cr, net profit ₹26 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

Others in Healthcare Equipment & Supplies this season

  • Vasa Denticity (Q2 FY27)

    Year-on-year revenue growth: Approximately 95.3% increase in revenue from Rs. Key results statement takeaways from Vasa Denticity Ltd's Q2 FY27 results statemen

  • Vaidya Sane (Q2 FY27)

    Year-on-year (YoY) change: +23% (from INR 687 Lakhs in Sep 2025) . Key results statement takeaways from Vaidya Sane Ayurved Laboratories Ltd's Q2 FY27 results s

  • Molbio Diagnosti (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹259.0 Cr vs ₹580.3 Cr in Q2 FY26 (significant decrease due to rate contract negotiations). Key investor presentation takeaways

  • Poly Medicure (Q2 FY27)

    Q2 FY27 consolidated revenue from operations: Rs 580.5 Cr, up 30.8% YoY (Q2 FY26: Rs 443.9 Cr). Key investor presentation takeaways from Poly Medicure Ltd's Q2

Compare:vs Poly Medicurevs Molbio Diagnostivs Fischer Medical

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sahajanand Medical Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sahajanand Medical Technologies Ltd Q2 FY27 results?

Revenue is expected to grow at mid to high teens in constant currency terms for current and next year. Revenue growth expected in mid to high teens in constant currency for FY 2027 and FY 2028.

What is Sahajanand Medical Technologies Ltd share price analysis?

Sahajanand Medical Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 69.8 with a market cap of ₹5,010 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sahajanand Medical Technologies Ltd planning capital expenditure?

Capex guidance for FY 2027 and FY 2028 is approximately INR 70 crores per year.

Keep Sahajanand Medical Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.